Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials
CONCLUSION: Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.INPLASY Reg. No.: INPLASY 202370097.PMID:38657982 | DOI:10.15537/smj.2024.45.4.20230728
Source: Saudi Medical Journal - Category: Middle East Health Authors: Xiangbo Shen Eryue Qiu Zhao Liu Xiaopeng Zhu Yiqian Zeng Source Type: research
More News: Bleeding | COVID-19 | Databases & Libraries | Middle East Health | Saudi Arabia Health | Study